FDA approves the Dexcom G5 mobile continuous glucose monitoring system for diabetes- Dexcom
The FDA has approved the G5 Mobile Continuous Glucose Monitoring (CGM) System, from Dexcom, for use in type 1 and 2 diabetes. With wireless Bluetooth technology built into the device transmitter, the G5 Mobile CGM System is the first fully mobile CGM system approved by the FDA for both adults and children as young as 2 years of age that sends glucose data directly to a smartphone, freeing users from the need to carry a separate receiver.
The new transmitter securely sends vital glucose information directly to an app on iOS-enabled devices for real-time diabetes management. Android applications will follow early next year. Like its predecessor, the G4 PLATINUM CGM with Share, users can also select up to five designated recipients, or "followers." These followers can remotely monitor a patient's glucose information and receive alert notifications from almost anywhere. The G5 Mobile system is anticipated to begin shipping in late September 2015 in the USA.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins